Drug Trial Radar · NCT03199560
Tilmanocept vs Sulfur Colloid in Sentinel Lymph Node Biopsy
Last checked: Nov 20, 2026Latest source record: Aug 24, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
86
Planned (sponsor's estimate)
Start
Jun 22, 2017
Primary completion
Jun 22, 2019
Study completion Aug 22, 2019
Sponsor
- Lead sponsor
- Memorial Health University Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 27, 2017
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A randomized controlled double-blinded study comparing the intraoperative injection of lymphatic mapping agents Tc 99m tilmanocept to Tc 99m filtered sulfur colloid in breast cancer patients undergoing breast conservation and sentinel lymph node biopsy
Conditions
- Sentinel Lymph Node Biopsy
- Breast Cancer
Interventions
Tc 99m tilmanoceptDrug
lymphatic mapping agent
Tc 99m filtered sulfur colloidDrug
lymphatic mapping agent
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of harvested lymph nodesTime frame: 1 day
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Memorial Health University Medical Center
Savannah, Georgia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.